about
Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tabletsValidating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydraminePrediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases.Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent.Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients.Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk.Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variabilityConfirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis.Microdosing and drug development: past, present and futureHallucinations and delirium in the dental office following triazolam administration.Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments.Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept.The emergence of new psychoactive substance (NPS) benzodiazepines: A review.Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism.Continuous midazolam infusion for the management of morphine-induced myoclonus.Local or general anesthesia for open hernia repair: a randomized trial.Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazolePsychiatric issues in renal failure and dialysis.Allergic and toxic reaction to alprazolam.Estimation of human drug clearance using multiexponential techniques.Effect of alosetron on the pharmacokinetics of alprazolam.Investigation of excipient type and level on drug release from controlled release tablets containing HPMC.Benzodiazepine in a urine specimen without drug metabolites.Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model.Midazolam daytime residual effect evaluated by the Multiple Sleep Latency Test.Plasma concentrations of midazolam during continuous subcutaneous administration in palliative care.
P2860
Q28239128-6B82BFEA-0E20-49BC-AF8C-9C896E0F1B5FQ30488931-4A23E8A8-D573-4687-A45D-3CC510ECD95EQ31012256-5264B880-B014-4B61-A758-171A8FCB6475Q31900846-FCC50117-F3FD-43BB-B71D-3E572D2485ACQ34156627-4B593273-76F6-418E-83E2-E188AEFD9857Q34346227-F612FC27-1490-40C3-9B10-DCEB79E8AC74Q34347407-000D20D4-2A69-4004-905D-8D68E36EBBE1Q34574831-2B989542-5578-48B1-8273-BF6DCAD22A11Q34622095-AA08CD37-036E-403C-BE7D-EC857681F656Q35940544-45D96AF0-A0D5-4071-8860-799E260F3E9DQ36109856-AA81318C-29D3-4852-9BB2-5511C1E7E47EQ36662893-D41F11FD-92E5-4AE9-86FA-E4187DB70823Q37437579-5FF761E7-1DC0-4016-B4C1-F511AD60F39FQ39282924-3D1F38E2-CDCC-47CB-ABCA-518AB3200DAAQ42155588-EF2BA375-145B-4EA9-94BE-08F10ECBC150Q42278548-E5245A06-E5D6-4E3C-A0CC-2D5680A298B8Q42596448-AC5DD7CA-4075-402D-ADAC-D5615C15936AQ42780390-A9666173-1554-42F9-933D-4A3FC9DFF91EQ42928181-CC40A9FC-255D-49F8-AC3A-4B9B4C626E1FQ43239037-F952D57F-5CBC-45B7-9ABD-7664CC557FFBQ43548556-6C5FBDD3-CEBE-4904-B3B1-B862EAB01E9EQ43576843-00F07743-53FF-4044-931A-A72148EED7E5Q44029373-97A99774-E891-4A15-80E2-95D57485BA4EQ46190747-176361A9-BAFF-40FC-95E7-B08A2B159D92Q46477546-2AAFFBB2-F170-461C-9B1D-71FFF6F9523DQ48869035-F351692E-EAED-43F0-9E2A-793C87AA0D60Q51646210-BD632466-3582-46DD-826B-96D92C76FD70
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Pharmacokinetics of the newer benzodiazepines.
@en
type
label
Pharmacokinetics of the newer benzodiazepines.
@en
prefLabel
Pharmacokinetics of the newer benzodiazepines.
@en
P1476
Pharmacokinetics of the newer benzodiazepines.
@en
P2093
Garzone PD
Kroboth PD
P304
P356
10.2165/00003088-198916060-00002
P577
1989-06-01T00:00:00Z
P6179
1052394911